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Promotion of access to essential medicines for 
non-communicable diseases: practical implications 
of the UN political declaration
Hans V Hogerzeil, Jonathan Liberman, Veronika J Wirtz, Sandeep P Kishore, Sakthi Selvaraj, Rachel Kiddell-Monroe, Faith N Mwangi-Powell, 
Tido von Schoen-Angerer, on behalf of The Lancet NCD Action Group 
Access to medicines and vaccines to prevent and treat non-communicable diseases (NCDs) is unacceptably low 
worldwide. In the 2011 UN political declaration on the prevention and control of NCDs, heads of government made 
several commitments related to access to essential medicines, technologies, and vaccines for such diseases. 30 years 
of experience with policies for essential medicines and 10 years of scaling up of HIV treatment have provided the 
knowledge needed to address barriers to long-term eﬀ  ective treatment and prevention of NCDs. More medicines can 
be acquired within existing budgets with eﬃ   cient selection, procurement, and use of generic medicines. Furthermore, 
low-income and middle-income countries need to increase mobilisation of domestic resources to cater for the many 
patients with NCDs who do not have access to treatment. Existing initiatives for HIV treatment oﬀ  er useful lessons 
that can enhance access to pharmaceutical management of NCDs and improve adherence to long-term treatment of 
chronic illness; policy makers should also address unacceptable inequities in access to controlled opioid analgesics. 
In addition to oﬀ  -patent medicines, governments can promote access to new and future on-patent medicinal products 
through coherent and equitable health and trade policies, particularly those for intellectual property. Frequent 
conﬂ  icts of interest need to be identiﬁ  ed and managed, and indicators and targets for access to NCD medicines 
should be used to monitor progress. Only with these approaches can a diﬀ  erence be made to the lives of hundreds of 
millions of current and future patients with NCDs. 
Introduction
Access to medicines and vaccines to prevent and treat 
non-communicable diseases (NCDs; mainly cardio-
vascular diseases, chronic respiratory diseases, diabetes, 
and cancer) is unacceptably low worldwide. Large 
disparities exist between high-income, middle-income, 
and low-income countries, and within countries, in access 
to medicines for NCDs and for infectious and acute 
diseases.
1 Mean availability of essential medicines in 
36 low-income and middle-income countries was about 
36% for NCDs versus 54% for acute diseases in the public 
sector, and 55% versus 66% (but at a much higher price) 
in the private sector.
2 The probability of patients receiving 
at least one medicine for secondary prevention of cardio-
vascular disease was 19·8% in low-income countries, 
30·7% in low-income and middle-income countries, and 
54·9% for upper-middle-income countries.
3 Why has 
substantial progress been made in global access to very 
costly medicines, such as antiretroviral drugs for HIV, but 
not for medicines for NCDs, which are largely oﬀ  -patent 
and cheap to produce? What can be done to make essential 
medicines, irrespective of patent status, aﬀ  ordable  for 
prevention and treatment for current and future patients?
We propose several measures to improve eﬃ   ciency in 
medicine supply within existing budgets, increase ﬁ  nan-
cing for NCDs, integrate pharmaceutical manage  ment for 
such diseases with existing initiatives, and ensure access 
to new and future essential medicines. Cross-cutting 
issues speciﬁ  c to NCD medicines are the management of 
frequent conﬂ  icts of interest and monitoring of progress. 
We refer to long-standing experiences with pharmaceutical 
policies for essential medicines in general and for 
antiretroviral medicines in particular, and apply the best 
experiences to NCDs. A particular issue is the insuﬃ   cient 
access to controlled opioid analgesics for pain relief and 
palliative care (panel 1). Much of our report could apply 
equally to medicines for mental health, which should also 
be a priority for global action; however, they are not 
discussed in this Series. 
Access to essential medicines
Access to essential medicines is an important aspect of 
development. It was part of the Alma Ata Declaration 
of 1978, and is one of the six targets of Millennium 
Development Goal (MDG) 8 (develop a global partner-
ship for development). This commitment was not 
conﬁ  ned to medicines for particular disorders, such as 
those speciﬁ   cally mentioned in MDG 5 (improve 
maternal health) and MDG 6 (combat HIV/AIDS, 
malaria, and other diseases). In 2007, the UN Secretary-
General established the MDG Gap Task Force to 
consolidate information about progress towards 
MDG 8. In each of its four annual reports
10–13 of MDG 8 
since 2008, the Task Force has noted the need for 
increased attention to access to medicines for NCDs. 
The 2008 report
10 contrasted the low level of support 
that had been given to NCD medicines compared with 
that given to other diseases. 
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Although access to medicines for NCDs has formally 
always been part of the MDGs, in practice it has been 
neglected. For example, the target is entirely missing 
from the 2007, 2009, 2010, 2011, and 2012 oﬃ   cial MDG 
reports (with access to treatment for HIV/AIDS, 
malaria, and tuberculosis reported as part of MDG 6). 
In the 2011 UN General Assembly Political Declaration 
on the Prevention and Control of NCDs,
14 states made 
several commitments relating to access to medicines, 
technologies, and vaccines, with additional commit-
ments for strengthening of health systems, health-care 
infrastructure, budgetary allocation, and universal 
coverage. In the Rio+20 Outcomes Document,
15,16 state 
oﬃ     cials committed to promote aﬀ   ordable access to 
prevention, treatment, care, and support for NCDs, and 
called for further national and international cooper-
ation to improve distribution and access to safe, 
aﬀ  ordable, eﬀ  ective, and quality medicines, vaccines, 
and medical technologies.
The right to the highest attainable standard of health 
was ﬁ   rst endorsed in WHO’s Constitution (1946),
17 
and was later included and expanded upon in several 
international treaties, including the International 
Covenant on Economic, Social and Cultural Rights 
(1966)
18 and the UN Convention on the Rights of the 
Child (1989).
19 The UN Political Declaration on NCDs 
reaﬃ   rmed the right of everyone to the highest attainable 
standard of physical and mental health. Access to 
medicines is a core component of the right to health
20 
and was recognised as such in UN General Assembly 
Resolution 64/25 to hold the high-level meeting on 
NCDs.
21 A rights-based approach to health can support 
national programmes for essential medicines to promote 
universal access.
22
In 2008, domestic constitutional or legislative endorse-
ment of access to essential medicines as part of the right 
to health became a WHO indicator to assess country 
progress.
23 In that year, 73% of the 186 national con-
stitutions included provisions for the right to health, and 
51% mentioned health facilities, goods, and services.
24 
Such legally binding obligations on governments can be 
especially relevant for NCDs, for which access to 
treatment is still so often deﬁ  cient. Patient-initiated court 
cases have resulted in governments including dis-
advantaged groups in their public services or nascent 
reimbursement schemes.
25 However, as noted in Latin 
America, excessive individual litigation can result in the 
allocation of resources to treat those with enough 
resources to start court proceedings,
26 undermining 
population-wide planning and resource allocation.
In May, 2012, the World Health Assembly adopted the 
global goal of a 25% reduction in preventable NCD 
deaths by 2025 (the 25 by 25 goal).
27 Access to medicines 
and vaccines is key to achievement of this goal. For 
example, a multidrug regimen based on opportunistic 
screening to prevent cardiovascular disease in high-risk 
individuals is estimated to result in prevention of almost 
18 million deaths (a ﬁ  fth from cardiovascular disease) in 
23 low-income and middle-income countries in the next 
10 years.
28 Investigators have suggested that in many 
middle-income countries, ﬁ   nancing for scaling up of 
Key messages 
•  Access to medicines is a core component of the right to health; this is especially 
relevant for long-term treatment of non-communicable diseases (NCDs). However, 
access to essential medicines and vaccines to prevent and treat NCDs is unacceptably 
low worldwide 
• Eﬃ   ciencies in improvement of access and aﬀ  ordability can be achieved within existing 
budgets. With the example of HIV, more medicines can be bought through generic 
policies, and better patient adherence to long-term treatment can be achieved with 
improved patient-centred care
•  Prepayment and risk sharing through tax-based or obligatory health insurance are the 
most eﬃ   cient ways to increase population coverage from domestic sources. Some 
low-income countries will need additional international ﬁ  nancing to address NCDs
•  Governments should ensure access to new, patented, and expensive NCD medicines 
through the full use of the ﬂ  exibilities of the Trade-Related Aspects of Intellectual 
Property Rights (TRIPS) agreement
•  Governments, intergovernmental organisations, and civil society need to aid and 
improve access to opioid analgesics for pain relief and palliative care
•  Civil society advocates, treatment guideline committees, and patient groups should 
identify and manage their frequent conﬂ  icts of interest in relation to the 
pharmaceutical industry
• Speciﬁ  c indicators and targets are needed to monitor country progress towards access 
to essential medicines
•  After 2015, access to medicines for NCDs should become a genuine priority in the 
development agenda, supported by resources, action, and systematic monitoring
Panel 1: Access to opioid analgesics
With increased attention to medicines for prevention and treatment of NCDs, priority 
should also be given to opioid analgesics for pain relief and palliative care. For access to 
opioid analgesics, disparity between high-income and low-income countries is especially 
high. The International Narcotics Control Board estimated that in 2009, more than 90% 
of the global consumption of opioid analgesics was in Australia, Canada, New Zealand, 
the USA, and some European countries, with less than 10% of global quantities used by 
the other 80% of the world’s population. The major barriers have long been known, and 
can be overcome. These barriers include insuﬃ   cient training of health-care professionals 
for the prescription and administration of opioids; misperceptions of health-care 
professionals, policy makers, and patients and their families about the safety of opioids; 
exaggerated fears about the development of dependence; overly restrictive laws and 
regulations that exceed the requirements of the UN Single Convention on Narcotic Drugs 
for the trade, distribution, and use of opioids; and unduly harsh sanctions for 
unintentional mishandling of opioids by heath workers. 
Substantial international developments have laid the groundwork for coordinated global 
action between governments, intergovernmental organisations, and civil society, 
including two resolutions of the UN Commission on Narcotic Drugs,
4,5 the Political 
Declaration’s recognition of palliative care, and major UN reports.
6–8 Progress has been 
made in many countries, including Uganda, Kenya, and Nigeria, through the joint eﬀ  orts 
of ministries of health, health-care workers, national palliative-care associations, regional 
networks, international non-governmental organisations and supporters, and the WHO 
Collaborating Centre, the Pain and Policy Studies Group.
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access to treatment is feasible from domestic sources, in 
view of the economic growth of these countries.
29 The so-
called best-buy NCD strategies for countries include 
pharmacotherapy for secondary prevention of cardio-
vascular disease, glycaemic control for diabetes, provision 
of aspirin for acute heart attack, and the hepatitis B 
vaccine for prevention of liver cancer.
27
What do countries need to do to improve access to 
medicines for NCDs to reach the 2025 target and to 
lay the foundations for progress after 2025? Because 
medicines are part of the six building blocks of health 
systems,
30 scaling up of access to medicines cannot be 
achieved in isolation,
31 but needs a comprehensive health 
system approach including, for example, pharmaceutical 
sector governance, appro priate pharmaceutical workforce 
training, pharmaceutical manage  ment information sys-
tems, procurement planning, and sustainable ﬁ  nancing 
of medicines.
32 
Increase eﬃ   ciency in selection, procurement, 
supply, and use to promote access to medicines 
within the existing health budget
Generic policies
Data from several countries show that access to 
medicines for NCDs can be substantially improved 
within existing budgets for pharmaceutical medicines 
by optimisation of the selection, procurement, supply, 
and use of medicines. For example, legislation can 
promote generic market entry and substitution, which 
are further facilitated by quality assurance systems to 
reassure prescribers and the public, price information 
promoting the ﬁ   nancial advantages of generics, and 
reimbursement schemes promoting generic sub-
stitution and reduced patient copayments for generic 
products. Policies that promote generic medicines can 
generate large savings; in France, implementation of a 
general generic substitution strategy saved nearly 
US$2 billion in 2008 alone.
29 Policies promoting the 
use of safe, aﬀ  ordable, eﬀ  ective, and quality generic 
medicines should address the eﬀ  ect of mark-ups and of 
poor purchasing practice, and any perception that low 
price equals low quality.
33,34
Rational selection
Selection of suitable medicines can also support generic 
products. In 2009, the Kyrgyzstan Government spent 
57% of its insulin budget on patented analogue insulins, 
which were used by only 13% of patients with diabetes.
35 
In 2011, WHO concluded that analogues had few 
advantages compared with generic human insulin and 
did not add them to its model list of essential medicines. 
If these patients were put back on generic insulin, twice 
the number of patients with diabetes could have been 
treated in Kyrgyzstan with the same budget. Hence, 
careful selection of medicines ﬁ   nanced by public or 
private ﬁ  nancing schemes is crucial to ensure eﬃ   cient 
procurement and use.
Most NCDs can be treated with a small range of oﬀ  -
patent medicines, such as analgesics, antihypertensives, 
cardiovascular drugs, statins, antiasthmatics, and some 
common anticancer drugs. However, some generic 
medicines are so cheap that they are no longer com-
mercially appealing and might stop being produced 
(panel 2). WHO’s model list of essential medicines and 
global model evidence-based clinical guidelines for the 
prevention and treatment of NCDs are periodically 
updated through assessments of potential new essential 
medicines.
37 The list is a guide for national committees 
that are responsible for identiﬁ  cation of the most cost-
eﬀ   ective medicines at country level for procurement, 
reimbursement, and treatment decisions, and helps to 
focus national eﬀ   orts towards universal coverage. A 
study
38 of 13 sub-Saharan African countries showed that 
only 38% of national lists were updated in the past 
5 years. The investigators noted that antihypertensive 
drugs on national lists were substantially cheaper than 
were those not included, underscoring the role of the 
national list in ensuring ﬁ  nancial accessibility.
Quality assurance 
Assurance of medicine quality is crucial to protect the 
population from potentially harmful medicines and 
reduce waste of resources. Because of inadequate 
regulation and insuﬃ   cient  penalisation,  substandard 
medicines are common in developing countries.
39,40 
Medicines for NCDs are no exception, as shown by the 
tragic incident in Pakistan in 2011, when contamination 
of isosorbide mononitrate led to more than 100 deaths.
41 
In Rwanda, 20% of hypertensive medicines purchased on 
the market were of substandard content and 70% were of 
insuﬃ   cient stability.
42 Although regulation of safe, quality 
medicines is a necessary investment by society to protect 
the public and support the domestic pharmaceutical 
industry, only about one in three regulatory agencies in 
Africa function adequately.
43 Some manufacturers take 
advantage of this unfortunate situation by exporting 
substandard medicines to other countries while being 
regulated for domestically marketed products.
40,44
The most eﬀ  ective long-term solution is that national 
medicines regulatory authorities receive increased 
Panel 2: Scarcity of access because medicines are not proﬁ  table enough
In some cases access to essential medicines is compromised because products are so cheap 
and demand so volatile that pharmaceutical companies might consider the sales not 
suﬃ   ciently proﬁ  table to be maintained. Examples for NCDs are thiazide diuretics and 
morphine. However, producers of aspirin in the USA and elsewhere have been able to survive 
on narrow margins when demand is predictable. Paediatric antiretroviral drugs are an 
example of how a small, fragmented, and unproﬁ  table market can be stabilised: the 
Clinton Foundation with funding from UNITAID stabilised the market through global pooled 
demand, generation of uptake at programme level, and donor funding for the drugs.
Production can also be threatened when global companies acquire high-end generic 
companies in India then shift production capacity towards more expensive products for 
the Indian market and for export to industrialised countries.
36Series
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political support and resources to protect patients. 
Worldwide, the success of the WHO programme to 
prequalify HIV/AIDS, tuberculosis, and malaria 
products for UN procurement cannot easily be extended 
to NCD medicines for which the market is so frag-
mented. Prequaliﬁ  cation works only when large global 
funds and procurement programmes or large national 
procurement agencies are interested in using global 
assessment reports of important products of which the 
quality, safety, and eﬃ   cacy is doubtful or unknown. For 
NCDs, the most likely candidate for inclusion would 
probably be generic human insulin, for which few 
international suppliers are available and for which 
diﬃ   culties exist for low-resourced regulators to assess 
quality. For other NCD medicines, the best solution 
might be for national procurement agencies to follow 
the well established quality assurance policies of the 
Global Fund to Fight AIDS, Tuberculosis and Malaria. 
This approach could be supported by the establishment 
of an independent system for the support, assessment, 
and endorsement of national and international procure-
ment agents and distributors,
45 or by the strengthening 
of a few eﬀ  ective regulatory authorities to regionally 
collaborate with countries with less capacity. Govern-
ments need to address the many political and ﬁ  nancial 
barriers to implementation of these strategies.
Monitoring of availability
Good monitoring systems for stock levels and use are 
crucial. Innovative use of communication technology, 
such as mobile telephones and short message service 
(SMS) messaging, could increase procurement eﬃ   ciency 
and monitoring. Community volunteers can track the 
availability of medicines in local facilities, and their SMS 
messages can feed into a website that helps to identify 
underperforming districts and start corrective action.
46 
Similar approaches for ﬁ  rst-line antimalarial drugs have 
resulted in a 50% decrease in facility stock-outs.
47 Such 
initiatives, if successful in the medium term, need to be 
scaled up.
Rational use 
Distribution challenges are often referred to as being the 
transport problem of the last mile, from district centre to 
village facilities. However, in practice the largest 
economic and public health losses, estimated at up to 
50% of the cost of medicine, often take place in the last 
metre—ie, in the interaction between the prescriber and 
patient and the direct purchase of medicines by con-
sumers. Approaches to improve the use of NCD 
medicines through prescription or over-the-counter use 
are the same as are those for other essential medicines.
48,49 
Such approaches include the strong recommendation to 
establish a dedicated national body to promote pre-
scribing guidelines, monitor medicine use, and provide 
education and independent information to prescribers, 
patients, and consumers, as is done in several countries. 
Examples are the National Prescribing Centre in the UK, 
the Belgian Centre for Pharma cothera peutic Information, 
and the Rational Use Directorate of the Sultanate of 
Oman. A particular issue with NCDs is the need to 
promote patient adherence to long-term treatment, as 
discussed later in this report.
Increase ﬁ  nancing for NCD medicines through 
domestic funding and international support
In low-income and middle-income countries, out-of-
pocket payments for medicines account for the largest 
proportion of household health expenditure.
29 For 
example, in Ghana, the lowest paid government worker 
will use 15 days’ wages to pay for 1 month of the lowest 
price hypertension and diabetes treatment from a private 
pharmacy.
50 Household surveys have shown that 41–56% 
of households in low-income and middle-income coun-
tries spend all their health-related expenditure on medi-
cines; poor households in these countries spend up to 
9·5% of their household expenditure on medicines 
compared with 3·5% by poor households in high-income 
countries.
51 Reliance on direct out-of-pocket ﬁ  nancing for 
chronic disorders needing daily treatment is a real 
economic threat to individuals and society as a whole, 
and is a substantial obstacle to increasing access to 
medicines for poor populations. 
Prepayment and risk sharing through tax-based or 
obligatory health insurance are the most eﬃ   cient and 
equitable ways to increase population coverage and 
promote equity.
29 Improved ﬁ  nancial  protection  for 
families against large medical bills reduces their risk of 
ﬁ  nancial ruin and increases security of their assets and 
savings; when many families beneﬁ  t, increased economic 
activity can stimulate improved economic develop-
ment.
29,52,53 Financing of access to medicines through 
universal health coverage, including for NCDs, is a top 
priority of the policy agenda in India. This agenda 
includes ensuring of domestic public and private ﬁ  nan-
cing, strengthening of the public sector, and ensuring of 
oversight in the private sector in which all initiatives 
should enhance equity and rational use.
54
What will it cost to provide access to medicines for 
NCDs? A WHO study
55 estimated a cost of $1 per person 
per year in low-income countries, less than $1·50 in 
lower-middle-income countries, and $2·50 in upper-
middle-income countries for individual best-buys of 
counselling and drug treatment for people at high risk of 
cardiovascular disease plus measures to prevent cervical 
cancer, in a scale-up period from 2011 to 2025. A previous 
report in 2009,
56 estimated the resources needed to 
achieve MDGs (including MDG 8e: access to essential 
medicines) in 49 low-income countries through strength-
en  ing of health systems and scaling up of service 
provision. Increased access to medicines for diabetes, 
chronic obstructive pulmonary disease, cardiovascular 
disease, and some cancers from their low levels in 2009, 
to at least 50% by 2015, will need an incremental cost of Series
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$6·93 per head (compared with countries reaching the 
MGD for HIV/AIDS, which would need an estimated 
investment of $10·24 per head).
56 
These additional costs should be considered in view of 
the present health expenditure per head of many 
countries. In the past few years, total per-head pharma-
ceutical expenditure on medicines has been $20·3 for 
low-income countries, $71·9 for lower-middle-income 
countries, and $152·0 for upper-middle-income coun-
tries, with high variation between income groups.
57 
Because many low-income and middle-income countries 
have moderate to strong economic growth, there is an 
especially clear case for increasing of domestic public 
funding, with at least $1–2·5 per head for the provision 
of essential medicines for NCDs to reach the 25 by 25 
goal. Although the full amount of nearly $7
56 might not 
be possible immediately, most middle-income countries 
could make a modest investment ﬁ  rst. 
Some of the poorest countries with low levels of health 
expenditure and little potential to increase their health 
budget in absolute terms might need to rely on external 
support to fund long-term NCD treatments; therefore, an 
additional international ﬁ  nancing mechanism is needed 
to safeguard the right to health of the poorest com-
munities. Unfortunately, an explicit ﬁ  nancial commit-
ment, such as that made by the global community for the 
AIDS epidemic in 2001,
58 was not forthcoming in the 
2011 UN high-level meeting on NCDs.
Integrate pharmaceutical management of NCDs 
with existing initiatives 
An especially important aspect for NCDs is the need to 
ensure patient adherence to long-term treatment. Patients 
cannot aﬀ  ord to travel far, especially when such travel 
expends 1 or more working days every month.
59 Long 
waiting times and frequent stock-outs do not support 
adherence. Public health systems need holistic patient-
centred care with appointment systems, evening opening 
hours, and task-shifting and down-referral of chronic 
treatment to rural facilities close to home. The same 
issues apply to HIV/AIDS, and there is a strong rationale 
to extend existing eﬀ  orts to ensure quality of care for HIV 
to patients with NCDs.
60 Simpliﬁ   ed monitoring and 
treatment regimens,
61 point-of-care tests,
62 decentralisation 
of care to the periphery, shifting of tasks from doctors to 
nurses,
63 and use of adherence counsellors instead of 
provider-controlled directly observed treatment
64 have all 
supported improved adherence.
65
The best-buy options for countries to reduce prevent-
able deaths from NCDs include management of 
cardiometabolic risk in high-risk individuals at the 
primary health-care level. The new polypill—a ﬁ  xed-dose 
combination of aspirin, a cholesterol-lowering drug, a 
β blocker, and an angiotensin-converting-enzyme 
inhibitor
66,67—might have the many noted advantages of 
ﬁ   xed-dose combinations for HIV, tuberculosis, and 
malaria, which have minimised prescribing errors and 
missed doses by patients while reducing costs by as 
much as 50% in some cases.
68 Furthermore, ﬁ  xed-dose 
combinations greatly simplify supply-chain management 
and patient education and counselling.
69,70 More studies 
of health and economic eﬀ  ects are needed to establish 
clearly whether the polypill for secondary prevention or 
high-risk primary prevention for cardiovascular diseases 
has advantages compared with use of multidrug 
regimens. If a consensus formulation is reached, the 
polypill regimen will emerge as a health priority by 2015.
Promote research and ensure access to new 
essential medicines for NCDs
Unlike the ﬁ  rst decade of AIDS treatment, most NCDs 
can be treated with inexpensive, oﬀ  -patent medicines. 
Securing of global access to oﬀ  -patent NCD medicines 
would already be an enormous achievement with 
profound eﬀ   ects on global health. However, access 
should also be ensured, when needed now and in the 
future, to newly developed, on-patent NCD medicines 
and vaccines, such as the HPV vaccine (panel 3). 
Important new NCD medicines are exceedingly 
expensive. For example, in the USA, the anticancer drugs 
erlotinib and rituximab cost $2400 and $13 000 per month, 
respectively.
71 Such expensive prices are largely because 
these treatments are under patent, which prevents 
generic competition. Most companies oﬀ  er  reduced 
prices to low-income and middle-income countries, but 
such voluntary mechanisms are less eﬀ  ective  than 
competition, as was shown for antiretroviral medicines 
for HIV.
72
Since 2005, the World Trade Organization’s (WTO) 
Trade-Related Aspects of Intellectual Property Rights 
(TRIPS) agreement has required 20-year product and 
process patent protection in all but the poorest of its 
Panel 3: Access to a new vaccine for human papillomavirus (HPV)
The HPV vaccine protects against HPV types 16 and 18, which cause about 70% of cervical 
cancer cases. The vaccine is important in low-income and middle-income countries where 
cancer screening and treatment services are often unavailable. However, only very few of 
these countries have introduced HPV vaccines into national programmes because of their 
high price and challenges to start a separate vaccination programme for adolescents. 
Rwanda, Bhutan, and most recently, Uganda have included the vaccine, but only because 
of donations from the pharmaceutical industry. 
The Global Alliance for Vaccines and Immunisation (GAVI) has played an important part in 
increasing procurement eﬃ   ciency. It has worked with manufacturers on strategies to 
reduce vaccine prices. As a result, in 2011, one manufacturer announced an indicative price 
oﬀ  er of US$5 per dose for low-income countries, a 64% reduction in the lowest public price. 
To ensure that girls in the poorest countries have access to the vaccine, GAVI and its 
partners are working with manufacturers within the UNICEF tender process to ensure a 
sustainable price for low-income countries. This example shows that markets for newly 
developed essential products can be created by pooled and donor-funded procurement, 
leading to increased volume and, ultimately, reduced prices. To ensure sustainable prices for 
low-income and middle-income countries, further price decreases through competition 
from expected Indian vaccine versions are important. Series
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member countries.
73 Innovator companies use the 
sequential launch of branded reformulations to maintain 
market dominance even when patents of the original 
invention have expired.
74 Not surprisingly, the contested 
politics of intellectual property and debate about access 
to medicines surfaced in negotiation of the political 
declaration on NCDs. The Doha Declaration on the 
TRIPS Agreement and Public Health
75 was adopted by 
WTO’s ministerial conference in 2001, in the context of 
widespread concern about the implications of TRIPS for 
aﬀ   ordability of medicines, particularly for HIV/AIDS. 
Without restriction to speciﬁ  c diseases or to epidemics, 
the Doha Declaration aﬃ     rmed that TRIPS “can and 
should be interpreted and implemented in a manner 
supportive of WTO members’ right to protect public 
health and, in particular, to promote access to medicines 
for all” and reaﬃ   rmed “the right of WTO members to 
use, to the full” TRIPS ﬂ  exibilities, including the power 
to grant compulsory licences.
75
In the negotiation of the political declaration on NCDs, 
there was disagreement between the USA and the 
European Union on the one side, and Brazil, India, 
Mexico, and other G77 members on the other about 
inclusion of references to the TRIPS agreement, the 
Doha Declaration, and the term epidemic.
76 This debate 
was yet another battle in long-running eﬀ  orts by these 
countries and originator pharmaceutical companies to 
conﬁ   ne the application of TRIPS’ ﬂ  exibilities  to 
medicines for infectious diseases.
77 Ultimately, although 
the political declaration aﬃ   rmed the full use of TRIPS 
ﬂ  exibilities for NCD medicines, the Doha Declaration 
was not speciﬁ  cally mentioned. The full use of TRIPS 
ﬂ   exibilities was reaﬃ     rmed in the Rio+20 outcome 
document, which did mention the Doha Declaration.
Fierce debates about the association between 
intellectual property laws and access to medicines for 
NCDs are taking place in Indian courts in relation to 
medicines for the treatment of chronic leukaemia and 
renal and hepatocellular carcinoma (panel 4). These 
court cases are of global relevance because the Indian 
pharmaceutical industry supplies many medicines to 
low-income and middle-income countries,
79 and is 
referred to as the pharmacy of the developing world. The 
continuing eﬀ  orts by the USA and European Union to 
include provisions stricter than those required by 
TRIPS
80 in trade negotiations, such as the Trans-Paciﬁ  c 
Partnership Agreement
81 and the EU-India Free Trade 
Agreement, are a serious concern. This issue is an area 
in which the political declaration’s recognition of the 
need for whole-of-government approaches across 
diﬀ  erent sectors should be applied.
Research needed to address NCDs includes develop-
ment of health technologies that are adapted to low-
resource settings. Identiﬁ  ed research and develop  ment 
needs include, for example, vaccines and safe and 
aﬀ  ordable medicines to address neglected cardiovascular 
diseases, such as rheumatic heart disease and Chagas 
disease (a cause of cardiovascular disease), and ﬁ  xed-
dose combination pills to manage diabetes and other risk 
factors for cardiovascular and renal disease.
82 Such 
research and development is typically neglected by 
industry because of low proﬁ   t. A proposal by WHO 
experts for a research and development treaty aims to 
address the research and development needs speciﬁ  c for 
developing countries, and will only be considered by the 
World Health Assembly in 2016.
83
Address conﬂ  icts of interest for all aspects of 
access to essential NCD medicines
One overarching and crucial challenge to promotion of 
access to NCD medicines is how to address conﬂ  icts of 
interest—ie, when commercial concerns might take 
precedence over public health interests. This Series in The 
Lancet examines the steps that governments can take to 
address conﬂ   icts of interest in policy making for the 
tobacco, alcohol, and ultra-processed food industries.
84 
Challenges for governments dealing with the pharma-
ceutical industry—which manufactures products that are 
essential for health—are very diﬀ  erent and in many ways 
more diﬃ     cult than are those encountered with other 
industries. This diﬀ  erence is shown in key international 
documents—eg, MDG 8e was devised in terms of “in 
cooper ation with pharmaceutical companies”. The Political 
Declaration calls on the private sector to “contribute to 
eﬀ  orts to improve access and aﬀ  ordability for medicines 
and technologies’”.
14 However, as noted in the HIV/AIDS 
crisis, this cooperation will not be easily attained. 
Selling of long-term treatment to expanding markets is 
undoubtedly a speciﬁ  cally important commercial interest 
Panel 4: Disputes about intellectual property and access to medicines for non-
communicable diseases in India
78
The Glivec case
Novartis was refused a patent in India for the crystalline salt form of imatinib (imatinib 
mesylate, brand-name Glivec) for chronic myeloid leukaemia, on the basis of section 3(d) 
of the 2005 Indian Patent Act, which allows for new forms of a known medicine to be 
patented only if the change shows signiﬁ  cantly improved therapeutic eﬃ   cacy compared 
with existing medicines. The Indian Patent Oﬃ   ce ruled that Glivec showed no signiﬁ  cant 
advantage compared with the old form. As a result, Indian generic companies can supply 
imatinib at US$124–174 per month, compared with the branded price of $2478 per 
month. An appeal by Novartis is being presented to the Supreme Court of India and could 
lead to easier patenting of modiﬁ  cations. If Novartis is successful, there could be 
far-reaching negative consequences for generic drug production for diﬀ  erent diseases.
The Nexavar case
Bayer was granted a patent in India on sorafenib tosylate (brand-name Nexavar) for renal 
and hepatocellular carcinoma. In March, 2012, the Indian Government issued a compulsory 
licence allowing an Indian company to produce a copy of the drug on the grounds that: 
(1) Bayer had not priced the drug at a level aﬀ  ordable to all Indian patients; and (2) Bayer had 
not ensured availability of suﬃ   cient quantities in India. The decision to grant a patent 
resulted in a price drop from more than US$5500 to $175 per month, and then to 
$125 per month. Reportedly, the US Government has expressed concern about India’s use of 
compulsory licensing. Bayer has appealed.Series
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for the pharmaceutical industry, and such interests can 
conﬂ   ict with those of public health. Previously, some 
individuals have criticised promotion of global treatment 
or screening targets that would bankrupt health systems 
even in high-income countries, and raised concerns that 
the deﬁ  nition of these targets was aﬀ  ected by the economic 
interests of some global corporations.
85 Conﬂ  icts of interest 
are also commonplace when specialists and patient 
organisations with close ties to pharmaceutical companies 
sit on the many NCD guideline committees. Formulary 
committee members, prescribers, and patient groups are 
faced with strong promotional pressures to recommend 
non-essential and high-cost medicines when lower-priced 
options are equally eﬀ  ective. There are suspicions that 
observational studies of nearly 360  000 patients with 
diabetes supported by one company are mostly serving a 
marketing purpose.
86
Governments and global health organisations are 
increasingly turning to industries, including the pharma-
ceutical industry, for ﬁ  nancial support. This reliance raises 
concerns about conﬂ  icts of interest that could threaten the 
legitimacy and eﬀ  ectiveness of decision making in global 
health. For communicable diseases, there are positive 
examples of public–private partnerships for contra  cept  ives 
and other technologies.
87 Additionally, health-policy 
researchers have proposed a model for NCDs that 
capitalises on such partnerships,
88 particularly as a 
suggested function of a partnership as emphasised in the 
political declaration on NCDs. Non-governmental organ-
isations have noted that government and public health 
institutions should avoid conﬂ  icts of interest in all aspects 
of governance.
89 To ensure the legitimacy of policy making, 
governments will need to ensure transparent and 
accountable processes in which stakeholders are equitably 
represented and all potential and actual conﬂ  icts of interest 
are explicitly identiﬁ  ed and systematically addressed. 
Legitimacy will also be improved by ensuring that 
people with NCDs are present to identify priority needs. 
Unfortunately, the NCD civil society movement is 
underdeveloped, and some patient groups have already 
compromised their independence and credibility by 
accepting pharmaceutical funding.
90 The availability of 
public and other non-commercial funding has often been 
key in allowing most HIV civil society groups to act only 
in the interests of people with HIV/AIDS. Therefore, 
public support for civil society groups for NCDs should 
be increased, which would reduce their dependence on 
commercial sources. 
For national agencies For international agencies and donors
Increase eﬃ   ciency in selection, 
procurement, supply, and use to 
promote access to medicines within 
the existing health budget
Develop evidence-based national clinical guidelines and a national list 
of essential NCD medicines for training, supply, and reimbursement
Promote use of generic NCD medicines through legislation, quality 
assurance, advocacy, and ﬁ  nancial incentives
Create a dedicated national body that is responsible for promotion of 
safe and eﬃ   cient use of medicines
Review laws and practices and remove unnecessary constraints on use 
of opioid analgesics
WHO should regularly update their model list of essential medicines and 
evidence-based model clinical guidelines for prevention and treatment of NCDs
WHO should include selected NCD medicines (eg, insulin) in the WHO/UN 
Prequaliﬁ  cation of Medicines Programme
WHO should increase their support to a few eﬀ  ective regulatory agencies in 
low-income and middle-income countries to collaborate with countries with 
less capacity
WHO, the UNODC, and the INCB should support countries to adopt and 
implement laws and policies that ensure the adequate availability and rational 
medical use of opioid analgesics
Finance NCD medicines through 
domestic funding, as part of 
universal access
Finance universal access to essential medicines for NCD through 
tax-based or obligatory health insurance schemes
High-income countries should establish an international ﬁ  nancing mechanism 
to support access to essential NCD medicines for the poorest communities in 
low-income countries with supportive public health policies
Integrate pharmaceutical 
management for NCDs with existing 
initiatives 
Establish patient-centred primary care delivery to enhance patient 
adherence to treatment
Use new communication technologies to monitor rural stocks of 
essential medical products
WHO and donors should promote and support research of cost estimations, 
operational research, and regulatory hurdles in the use of a multidrug regimen 
versus the polypill for high-risk prevention of cardiovascular disease in 
low-income and middle-income countries
Donors should facilitate integration of NCD medicines into other 
medicines initiatives
Ensure access to new essential 
medicines for NCDs
Use ﬂ  exibilities of the TRIPS agreement and resist pressure to adopt 
higher intellectual property standards than required by the TRIPS 
agreement 
Member states and WHO should support the development of international 
agreement to ﬁ  nance research and development for diseases that mostly aﬀ  ect 
people in low-income and middle-income countries
Address conﬂ  icts of interest for all 
aspects of promotion of access to 
essential NCD medicines
Ensure transparent and accountable processes in which potential and 
actual conﬂ  icts of interest are explicitly identiﬁ  ed and addressed
Increase public support for civil society groups, reducing their 
dependence on commercial sources
International agencies and donors should identify and manage all potential 
conﬂ  icts of interest for NCDs, and ensure consultation and participation of 
publicly funded independent patient and consumer representatives in all 
relevant policy fora
Monitor progress Establish or empower an existing national body to monitor 
appropriate use of medicines and patient adherence to NCD treatment 
and prevention
Monitor the proportion of the population unable to access essential 
NCD medicines
The UN should increase reporting in the MDG reports of access to essential 
medicines for NCDs
Member states should agree and work consistently toward a target for access to 
NCD medicines in the NCD global monitoring framework
Member states and the UN should adequately monitor access to medicines for 
NCDs as part of the post-2015 development agenda
NCD=non-communicable disease. TRIPS=Trade-Related Aspects of Intellectual Property Rights. UNODC=UN Oﬃ   ce on Drugs and Crime. INCB=International Narcotics Control Board. MDG=Millennium 
Development Goal.
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Monitor progress towards access to medicines 
for NCDs 
Development of indicators, benchmarks, and targets is an 
important component of the rights-based approach and 
allows communities to hold their governments account-
able.
91 Setting of targets and monitoring of progress for 
HIV has been an important way to track ﬁ  nancial 
investments, treatment outputs, and health outcomes for 
this disease.
92 In November, 2012, WHO member states 
agreed on a set of indicators for medicines and technologies 
for NCDs: (1) drug treatment to prevent heart attacks and 
strokes (including for glycaemic control); (2) the availability 
of generic essential NCD medicines and basic technologies 
in public and private facilities; (3) access to palliative care; 
and (4) vaccination against human papillomavirus and 
hepatitis B virus as infectious causes of cancer.
93 A 
voluntary target for drug treatment to prevent heart attacks 
and stroke is that 50% of eligible people receive drug 
therapy and counselling; for availability of generic essential 
NCD medicines, the member states agreed on 80% 
availability in public and private facilities.
93
Many countries have already collected ad-hoc facility-
based information about price and availability of NCD 
medicines.
94 Routine monitoring systems should now 
be established, which would not only provide such 
facility-based information regularly, but would also 
provide information about the quality and eﬃ   ciency of 
use of medicines. Furthermore, the proportion of the 
population who cannot access NCD medicines when 
needed, and the amount of out-of-pocket expenditure 
for NCD medicines, should be monitored. Countries 
should add these questions to their routine household 
surveys to monitor the eﬀ  ect of their investments in 
NCDs. Such speciﬁ  c indicators and targets for access to 
NCD medicines will ﬁ  ll the gap of quantitative data that 
has made meaningful reporting of MDG 8e so diﬃ   cult 
until now.
10
Conclusions
In the UN political declaration, states have committed 
to enhancing access to safe, aﬀ  ordable, eﬀ  ective, and 
quality medicines for NCDs. 30 years of experience with 
essential medicines policies and scaling up of treatment 
for HIV/AIDS have provided the knowledge to address 
barriers to long-term quality treatment. But what does 
success look like for 2025? Millions of patients still do 
not have access to life-saving vaccines, treatments, and 
basic palliation, so what will change? We envision a 
helical strategy in which commitments built on existing 
initiatives and those speciﬁ   c to NCDs are strongly 
supported by countries and international agencies to 
ensure access to essential treatments (table). At a 
minimum, such support will enable achievement of the 
target of 80% national availability of quality essential 
medicines for NCDs in public and private health 
facilities worldwide, and the target of 50% of eligible 
people receiving drug treatment and counselling to 
prevent heart attacks and stroke, with progress towards 
WHO’s global 25 by 25 mortality target. 
Success is dependent on the crucial pathways outlined 
in this report: leveraging of eﬃ   ciencies  in  selection, 
procurement, and use of oﬀ   -patent medicines; and 
increased funding for medicines, including those from 
domestic sources. Pharmaceutical management should 
be integrated with existing initiatives for other diseases, 
including HIV and AIDS, and inequities in access to 
controlled opioids for palliation should be redressed. 
Countries should guarantee access to on-patent medical 
products by full use of ﬂ   exibilities in the TRIPS 
agreement, and conﬂ  icts of interest should be identiﬁ  ed 
and managed carefully. After 2015, access to medicines 
for NCDs should move from a neglected part of the 
development agenda to a genuine priority, supported by 
action, resources, and systematic monitoring. If these 
steps are taken, the right to health will be aﬃ   rmed across 
borders, generations, and populations to enable access to 
essential treatments by millions of current and future 
patients with NCDs. Such a new approach to NCDs 
requires that each individual counts; no-one should be 
left behind.
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